Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.
- Author:
Bo DAI
1
;
Ding-Wei YE
;
Yun-Yi KONG
;
Yi-Jin SHEN
;
Bo-Hua WANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Biopsy, Needle; China; Humans; Male; Middle Aged; Prostate; pathology; Prostate-Specific Antigen; blood; Prostatic Neoplasms; blood; pathology
- From: Asian Journal of Andrology 2008;10(2):325-331
- CountryChina
- Language:English
-
Abstract:
AIMTo evaluate the best individualized prostate biopsy strategies for Chinese patients with suspected prostate cancer.
METHODSThe present study included 221 Chinese patients who underwent transrectal ultrasound guided prostate biopsies for the first time. All patients underwent the same 10-core biopsy protocol. In addition to the Hodge sextant technique, four more biopsies were obtained from the base and middle regions of bilateral peripheral zones. The differences between 10-core and sextant strategies in cancer detection among patients with different prostate specific antigen (PSA) levels were evaluated. The relationship between PSA level, number of positive biopsy cores and organ-confined cancer rate in prostate cancer patients was also analyzed.
RESULTSThe overall prostate cancer detection rate was 40.7% in the 221 patients. The 10-core strategy increased cancer detection by 6.67% (6/90) in our patients (P < 0.05). The increased cancer detection rates decreased significantly when the patient PSA level increased from 0-20 ng/mL to 20.1-50 ng/mL and > 50 ng/mL (P < 0.01). The number of positive biopsy cores in prostate cancer patients increased significantly with increasing patient PSA level (P < 0.01). The rate of organ-confined prostate cancer decreased significantly with increasing patient PSA level (P < 0.01).
CONCLUSIONThe extended 10-core strategy is recommended for Chinese patients with PSA = or < 20 ng/mL and the sextant strategy is recommended for those with PSA > 50 ng/mL. For patients with PSA ranging from 20.1 ng/mL to 50 ng/mL, the 10-core strategy should be applied in patients with life expectancy = or > 10 years and the sextant strategy should be applied in those with life expectancy < 10 years.